CEO and executive chairman appointed at iPierian
This article was originally published in Scrip
iPierian, a biopharmaceutical company, has appointed Dr Nancy Stagliano CEO, while the company's interim CEO, Dr Peter van Vlasselaer will become executive chairman of the board of directors. Dr Stagliano joins iPierian after serving as CEO and co-founder of CytomX Therapeutics.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.